{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:39:06Z","timestamp":1790069946679,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"The Belgian Technical Cooperation (BTC\/CTB"},{"name":"Belgian Acad\u00e9mie pour la Recherche et l\u2019Enseignement Sup\u00e9rieur (ARES)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jpba.2017.02.040","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T04:32:08Z","timestamp":1487910728000},"page":"8-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Application of design space optimization strategy to the development of LC methods for simultaneous analysis of 18 antiretroviral medicines and 4 major excipients used in various pharmaceutical formulations"],"prefix":"10.1016","volume":"139","author":[{"given":"V\u00e9daste","family":"Habyalimana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie Kindenge","family":"Mbinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille Loconon","family":"Yemoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Waffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tidiane","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicod\u00e8me Kalenda","family":"Tshilombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin-L\u00e9onard Kadima","family":"Ntokamunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lebrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Hubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland Djang'eing'a","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2017.02.040_bib0005","unstructured":"World Health Organization, 10 facts on HIV\/AIDS (updated July 2016): http:\/\/www.who.int\/features\/factfiles\/hiv\/en\/."},{"key":"10.1016\/j.jpba.2017.02.040_bib0010","unstructured":"World Health Organization, HIV\/AIDS Fact sheet (updated July 2016): http:\/\/www.who.int\/mediacentre\/factsheets\/fs360\/en\/."},{"key":"10.1016\/j.jpba.2017.02.040_bib0015","unstructured":"World Health Organization (WHO): Counterfeit triple antiretroviral combination product (Ginovir 3D) detected in Cote d'Ivoire: Information Exchange System Alert No 110. Geneva: WHO; 2003. QSM\/MC\/IEA.110."},{"key":"10.1016\/j.jpba.2017.02.040_bib0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0140-6736(04)15670-5","article-title":"Antidepressants are sold as antiretrovirals in DR Congo","volume":"363","author":"Ahmad","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2017.02.040_bib0025","unstructured":"http:\/\/www.irinnews.org\/report\/94012\/kenya-government-grapples-counterfeit-arvs."},{"key":"10.1016\/j.jpba.2017.02.040_bib0030","unstructured":"World Health Organization, Prequalification of Medicines Programme. http:\/\/apps.who.int\/prequal\/info_press\/documents\/Falsified_ZidolamN_23September2011.pdf."},{"key":"10.1016\/j.jpba.2017.02.040_bib0035","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.chroma.2011.05.102","article-title":"Innovative high-performance liquid chromatography method development for the screening of 19 antimalarial drugs based on a generic approach, using design of experiments, independent component analysis and design space","volume":"1218","author":"Debrus","year":"2011","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2017.02.040_bib0040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4236\/ajac.2015.62012","article-title":"Fighting poor quality medicines: development, transfer and validation of generic HPLC methods for analyzing two WHO recommended antimalarial tablets","volume":"6","author":"Mbinze","year":"2015","journal-title":"Am. J. Anal. Chem."},{"key":"10.1016\/j.jpba.2017.02.040_bib0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.chemolab.2007.05.010","article-title":"Development of a new predictive modelling technique to find with confidence equivalence zone and design space of chromatographic analytical methods","volume":"91","author":"Lebrun","year":"2008","journal-title":"Chemom. Intell. Lab. Syst."},{"key":"10.1016\/j.jpba.2017.02.040_bib0050","unstructured":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Q8 (R2): Pharmaceutical Development, Aug. 2009. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q8_R1\/Step4\/Q8_R2_Guideline.pdf."},{"key":"10.1016\/j.jpba.2017.02.040_bib0055","first-page":"579","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal \u2013 part I","volume":"36","author":"Hubert","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.02.040_bib0060","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpba.2007.06.013","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal \u2013 part II","volume":"45","author":"Hubert","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.02.040_bib0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jpba.2007.06.032","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal \u2013 part III","volume":"45","author":"Hubert","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.02.040_bib0070","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jpba.2008.07.018","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal: part IV \u2013 examples of application","volume":"48","author":"Hubert","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.02.040_bib0075","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology Q2 (R1), November 2005. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q2_R1\/Step4\/Q2_R1__Guideline.pdf."},{"key":"10.1016\/j.jpba.2017.02.040_bib0080","unstructured":"R\u00e9publique du Rwanda, Minist\u00e8re de la Sant\u00e9, La liste nationale des m\u00e9dicaments essentiels, 5\u00e8me \u00e9dition, Juillet 2010. http:\/\/apps.who.int\/medicinedocs\/documents\/s17569fr\/s17569fr.pdf."},{"key":"10.1016\/j.jpba.2017.02.040_bib0085","unstructured":"Republic of Rwanda, ministry of Health, National List of Essential Medicines for Adults, 6th Edition, 2015. http:\/\/moh.gov.rw\/fileadmin\/templates\/Docs\/NEML_For_Adults_6th_Edition_2015.pdf."},{"key":"10.1016\/j.jpba.2017.02.040_bib0090","unstructured":"Republic of Rwanda, Ministry of Health, National List of Essential Medicines for Paediatrics, 1st Edition, 2015. http:\/\/moh.gov.rw\/fileadmin\/templates\/Docs\/NEML_For_Paediatrics-_1st_Edition-2015.pdf."},{"key":"10.1016\/j.jpba.2017.02.040_bib0095","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ejpb.2007.06.018","article-title":"HPLC calculator v3.0: software for chromatographic performance evaluation and HPLC method transfer","volume":"68","author":"Guillarme","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2017.02.040_bib0100","unstructured":"R Development Core Team, The R Project for Statistical Computing. http:\/\/www.r-project.org\/ ; https:\/\/cran.r-project.org\/bin\/windows\/base\/old\/3.2.2\/."},{"key":"10.1016\/j.jpba.2017.02.040_bib0105","unstructured":"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/20564s14,20596s15lbl.pdf."},{"key":"10.1016\/j.jpba.2017.02.040_bib0110","unstructured":"https:\/\/www.medicines.org.uk\/emc\/medicine\/362."},{"key":"10.1016\/j.jpba.2017.02.040_bib0115","unstructured":"http:\/\/apps.who.int\/prequal\/whopar\/whoparproducts\/HA431Part6v1.pdf."},{"key":"10.1016\/j.jpba.2017.02.040_bib0120","unstructured":"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/20636s025,20933s014lbl.pdf."},{"key":"10.1016\/j.jpba.2017.02.040_bib0125","unstructured":"http:\/\/apps.who.int\/prequal\/whopar\/whoparproducts\/HA382part5v1.pdf https:\/\/www.medicines.org.uk\/emc\/medicine\/2475."},{"key":"10.1016\/j.jpba.2017.02.040_bib0130","unstructured":"https:\/\/www.medicines.org.uk\/emc\/medicine\/15810."},{"key":"10.1016\/j.jpba.2017.02.040_bib0135","unstructured":"European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), Reflection paper on the use of methyl- and propylparaben as excipients in human medicinal products for oral use. EMA\/CHMP\/SWP\/272921\/2012, 22 October 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/11\/WC500196733.pdf."},{"key":"10.1016\/j.jpba.2017.02.040_bib0140","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0014-827X(03)00079-X","article-title":"The safety of pharmaceutical excipients","volume":"58","author":"Pifferi","year":"2003","journal-title":"Il Farmaco"},{"key":"10.1016\/j.jpba.2017.02.040_bib0145","unstructured":"http:\/\/www.inchem.org\/documents\/jecfa\/jeceval\/jec_258.htm."},{"key":"10.1016\/j.jpba.2017.02.040_bib0150","unstructured":"http:\/\/www.inchem.org\/documents\/jecfa\/jeceval\/jec_259.htm."},{"key":"10.1016\/j.jpba.2017.02.040_bib0155","unstructured":"International Pharmacopoeia - Six Edition, 2016 \u2013 Zidovudine oral solution; Zidovudine and lamivudine tablets; Zidovudine, lamivudine and abacavir tablets; Zidovudine, lamivudine and nevirapine tablets; Paediatric didanosine liquid for oral use; Emtricitabine and tenofovir tablets; Efavirenz, emtricitabine and tenofovir tablets; Lopinavir and ritonavir tablets; Nevirapine oral suspension. http:\/\/apps.who.int\/phint\/en\/p\/about\/."},{"key":"10.1016\/j.jpba.2017.02.040_bib0160","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.jchromb.2009.06.019","article-title":"A risk-based analysis of the AAPS conference report on quantitative bioanalytical methods validation and implementation","volume":"877","author":"Boulanger","year":"2009","journal-title":"J. Chromatogr. B"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516313164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516313164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:41:13Z","timestamp":1538008873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708516313164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":32,"alternative-id":["S0731708516313164"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2017.02.040","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of design space optimization strategy to the development of LC methods for simultaneous analysis of 18 antiretroviral medicines and 4 major excipients used in various pharmaceutical formulations","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2017.02.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}